# Phico Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/phico-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.phicotx.co.uk
- Total disclosed funding: $0.7M
- Latest round: Series A (Aug 1, 2002)
- Investors on record: 4

## About

Phico Therapeutics Ltd. is a biotechnology company focused on developing innovative therapeutic solutions for infectious diseases, primarily targeting antibiotic-resistant infections through advanced anti-infective technologies.Founded in 2000 in Cambridge, UK, Phico Therapeutics Ltd. specializes in the development of therapeutic products aimed at combatting infectious diseases. The company has not undergone any notable pivots and operates independently without subsidiaries. The founder, German Campuzano, has a history in the life sciences sector. As of May 2021, Phico Therapeutics raised GBP 7 million in a funding round led by Business Growth Fund, bringing the total amount raised to GBP 7 million across 15 deals.Phico Therapeutics specializes in developing innovative therapeutic products targeting infectious diseases, focusing on anti-infective technologies. Their flagship product, SASPject, utilizes natural antibacterial properties to address antibiotic-resistant infections, particularly those caused by Clostridium difficile. The company serves healthcare providers, hospitals, and pharmaceutical companies involved in infectious disease management in North America and Europe, enhancing patient outcomes through strategic partnerships and research collaborations.Phico Therapeutics generates revenue through collaborations, partnerships, and licensing agreements, which include milestone payments tied to developmental and regulatory achievements, as well as future sales royalties. The company’s financial model also involves direct partnerships with hospitals for SASPject implementation and agreements with larger pharmaceutical firms for co-development and commercialization of its products, aligning pricing with industry standards.Phico Therapeutics plans to utilize the GBP 7 million raised in May 2021 to further develop its lead product PT3.9 towards clinical stages. The company is also focused on expanding into new markets, particularly in North America and Europe, as part of its strategy to introduce new therapeutic solutions. This funding will support ongoing research and development efforts essential for bringing innovative products to market.

## Funding rounds

- Series A, Aug 1, 2002, $0.7M — Cambridge Capital Group, CRIL, Providence Investment Company, EMBLEM Technology Transfer
- Seed, Sep 1, 2000 — CRIL

## Investors

- CRIL (https://capitalatlas.ai/funds/cril) — Seed, Series A
- Cambridge Capital Group — Series A
- Providence Investment Company — Series A
- EMBLEM Technology Transfer (https://capitalatlas.ai/funds/emblem-technology-transfer) — Series A